Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2005
03/17/2005US20050058622 Preconditioning, ablation compound such as interleukins, colony stimulating factor
03/17/2005DE10337863A1 Verwendung von Chromen-4-on-Derivaten The use of chromene-4-one derivatives
03/17/2005CA2538382A1 Antimicrobial compositions and methods
03/17/2005CA2537763A1 Treatment for cd5+ b cell lymphoma
03/17/2005CA2537290A1 Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
03/17/2005CA2537226A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
03/17/2005CA2537096A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
03/17/2005CA2536874A1 Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
03/17/2005CA2536669A1 Methods for intradermal delivery of therapeutics agents
03/17/2005CA2532941A1 Composition and method for facilitating bone healing
03/17/2005CA2532161A1 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases
03/16/2005EP1514942A1 Method of searching substane having antidiabetic activity
03/16/2005EP1514925A1 Method of screening compound affecting amyloid beta production
03/16/2005EP1514556A1 Botulinum toxin pharmaceutical compositions
03/16/2005EP1514550A2 Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
03/16/2005EP1514548A2 Use of cloprostenol fluprostenol, and their analogues to treat glaucoma and ocular hypertension
03/16/2005EP1514543A1 Combination therapy comprising atorvastatin and an antihypertensive agent
03/16/2005EP1514542A1 Medicinal compositions improving brain function and method for improving brain function
03/16/2005EP1514536A1 Topical compositions
03/16/2005EP1514116A1 Oxaliplatin anti-resistance agent
03/16/2005EP1513959A2 Antiviral inhibitions of capsid proteins
03/16/2005EP1513870A2 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same
03/16/2005EP1513840A2 Compounds and compositions for the treatment of diabetes and diabetes-related disorders
03/16/2005EP1513818A2 Heterocyclic inhibitors of kinases
03/16/2005EP1513808A2 Fluorinated cyclic amides as dipeptidyl peptidase iv inhibitors
03/16/2005EP1513807A1 Pharmaceutical combination
03/16/2005EP1513797A1 Agents and methods for the treatment of disorders associated with oxidative stress
03/16/2005EP1513589A1 1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
03/16/2005EP1513587A1 Self-administered contraceptive injection of oily solution
03/16/2005EP1513548A2 Method for reducing obstructive hydrocephalus
03/16/2005EP1513546A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
03/16/2005EP1513536A1 Use of compounds that stimulate cgmp
03/16/2005EP1513529A1 Triple monoamine reuptake inhibitors for the treatment of chronic pain
03/16/2005EP1513525A1 Use of mglur5 antagonists for the treatment of gerd
03/16/2005EP1513523A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
03/16/2005EP1513522A2 Methods of treating conditions associated with an edg receptor
03/16/2005EP1513520A2 Substituted pyrrolines as kinase inhibitors
03/16/2005EP1513519A1 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
03/16/2005EP1513518A1 Use of nefopam for the treatment of nausea or emesis
03/16/2005EP1513517A1 Formulation of nefopam and its use in the treatment of pain
03/16/2005EP1513509A2 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
03/16/2005EP1513507A1 Transdermal analgesic systems with reduced abuse potential
03/16/2005EP1513502A1 Combination therapy for respiratory disorders
03/16/2005EP1513493A2 Analgesics
03/16/2005EP1513486A1 Composition for enhancing oral health
03/16/2005EP1513481A2 Throat spray
03/16/2005EP1513419A2 Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
03/16/2005EP1453510A4 Neurotransmitter balance chemotherapy
03/16/2005EP1435899A4 A composition for promoting hair growth
03/16/2005EP1353693B1 Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
03/16/2005EP1242095A4 Antimicrobial compositions and methods of use
03/16/2005EP1226119B1 Tyrosine kinase inhibitors
03/16/2005EP1216039B1 Novel combination for the treatment of sexual dysfunction
03/16/2005EP1204423B1 Therapeutic antibody against muc-1 antigen and methods for their use
03/16/2005EP1146873B1 Anti-androgens and methods for treating disease
03/16/2005EP1140054B1 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
03/16/2005EP1135134B1 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
03/16/2005EP1096975B1 Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
03/16/2005EP0948609B1 Llg polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
03/16/2005EP0942746B1 Inhibition of invasive remodelling
03/16/2005EP0808164B1 Use of prolactin modulators and diet for the manufacture of a medicament for the treatment of obesity
03/16/2005EP0774964B1 Controlled local delivery of chemotherapeutic agents for treating solid tumors
03/16/2005CN1596312A Antibiotics GE 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof
03/16/2005CN1596269A A novel G protein-coupled receptor, gave 10
03/16/2005CN1596266A Specific binding agents of human angiopoietin-2
03/16/2005CN1596264A Differentially expressed genes associated with obesity and type 2 diabetes
03/16/2005CN1596258A Adenosine A2a receptor antagonists
03/16/2005CN1596257A Novel crystalline compound
03/16/2005CN1596127A Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
03/16/2005CN1596121A Prevention and treatment of restenosis by local administration of drug
03/16/2005CN1596119A Modification of feeding behavior
03/16/2005CN1596115A Treatment of hyperproliferative diseases using active vitamin D analogues
03/16/2005CN1596111A Methods and compositions for ameliorating the undesirable effects of chemotherapy
03/16/2005CN1594358A Method for reducing or inhibition of proliferation of oncogenic cells and compound used in it (variants)
03/16/2005CN1193003C Aminobenzophenones as inhibitors of IL-1 beta and TNF-alpha
03/16/2005CN1192796C Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
03/15/2005US6867305 For cancer therapy
03/15/2005US6867299 Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents
03/15/2005US6867247 Medical devices and applications of polyhydroxyalkanoate polymers
03/15/2005US6867231 Therapeutic systems
03/15/2005US6867218 An arylene or heteroarylene alkoxy or hydroxy-propionic acid or ester derivatives; treatment or prevention of Peroxisome Proliferator-Activated Receptors; diabetes, impaired glucose tolerance, insulin resistance or obesity
03/15/2005US6867215 Cardioprotective phosphonates and malonates
03/15/2005US6867201 For therapy of abnormal cell growth, such as cancer, in mammals
03/15/2005US6867192 Inhibiting eosinophil infiltration into lungs; such as 2-((-2-((2-(2-Benzoylphenoxy)acetyl)amino)-4-methylpentanoyl)-amino)-3-(4 -(((4-((2-phenylacetyl)amino)-1-piperidinyl)-carbonyl)oxy)phenyl)propanoic acid
03/15/2005US6867184 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
03/15/2005US6867182 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof
03/15/2005US6867003 Grb14, Grb14 fusion proteins, and screening methods
03/15/2005US6866869 Liquid antimicrobial compositions
03/15/2005US6866864 Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
03/15/2005US6866856 Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
03/15/2005US6866843 Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
03/15/2005US6866842 Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
03/15/2005US6866838 Composite nanospheres and their conjugates with biomolecules
03/15/2005CA2382549C Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
03/15/2005CA2317769C Sustained release microparticle and method for preparing the same
03/15/2005CA2217515C Pharmaceutical composition containing proton pump inhibitors
03/12/2005CA2440784A1 Anti-bacterial, anti-viral, and anti-fungus composition, its preparation and use
03/10/2005WO2005021750A1 Treatment of menorrhagia, dysmenorrhoea or endometriosis
03/10/2005WO2005021706A2 Delivery of compounds with rehydrated blood cells
03/10/2005WO2005021518A1 Condensed ring compound and use thereof
1 ... 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 ... 1151